Metacrine
IPO
Nuclear receptor therapies for liver and metabolic disease
- Headquarters
- San Diego, California
- Employees
- 11–50
- Founded
- 2015
- Business Model
- B2B
- Website
- metacrine.com
- Total Funding
- $123.0M
- Last Round
- $65.0M Series CJun 2018
About
Metacrine is a clinical-stage biopharmaceutical company focused on developing therapies for patients with liver, gastrointestinal, and metabolic diseases. The company targets nuclear receptors involved in disease pathways, with a pipeline aimed at conditions such as NASH and inflammatory bowel disease.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account